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INTRODUCTION
The  standard  level  1  and  2  axillary  lymph  node  dissection  (ALND)  has  been  a  routine 
component of the surgical care of the breast cancer patients over the past century, by providing the 
prognostically powerful  definitive  proof  of  axillary node  negative  v/s  positive disease historically, 
ALND with  surgical removal of nodal metastases in level 1&2 of the axilla was thought to aid in 
achieving excellent local –regional control of disease in breast cancer patients the extent to which an 
ALND contributes to breast cancer survival, however, is uncertain. The prognostic and staging benefits 
of the ALND must be weighted against the acknowledged morbidity associated with the procedure. 
When suitable alternatives to ALND were considered,  clinical  examination and imaging modalities 
failed to  consistently stage the axilla  with accuracy.  As a  result  intraoperative lymphatic  mapping 
(IOLM)rapidly emerged as  a primary approach to staging the axilla .
Sentinel lymph node biopsy (SLN) has proven to be an accurate and less morbid, minimally 
invasive approach to evaluating the status of axillary lymph nodes. Many institutions have come to 
accept a negative SLN as accurate means of identifying the node negative patients for whom the ALND 
can be avoided .a completion ALND remains standard care for a patient who has a positive SLN
                                            AIMS OF STUDY 
The aims of this study are to determine
1. To study the incidence of Sentinel Lymph Node Biopsy positivity for Carcinoma Breast, by 
using methyline blue dye in Govt. Rajaji Hospital, Madurai.
2. Investigations done and their usefulness in clinching the diagnosis.
3. The treatment offered and the outcome.
OVER VIEW OF CARCINOMA OF THE BREAST 
 Breast Cancer is the most common cause of death in middle aged women in Western countries. 
In 1998, approximately one million new cases were diagnosed worldwide.  In England and Wales, one 
in 12 women will develop the diseases during their lifetime. 
Investigation of a breast Lump  (after imaging performed) Using fine – needle aspiration with cytology.
By age 25 1 in 19 608 By age 60 1 in 24
By age 30 1 in  2525 By age 65 1 in 17
By age 35 1 in 622 By age 70 1 in 04
By age 40 1 in 217 By age 75 1 in 11
By age 45 1 in 93 By age 80 1 in 10
By age 50 1 in 50 By age 85 1 in 9
By age 55 1 in 33 Ever 1 in 8
Aetiological factors:
Geographical :
It  occurs commonly in the Western World, accounting for 3-5% of deaths, yet is rare tumour in 
Japan.  In developing countries, it accounts for 1 to 3 % of deaths. 
Age
Carcinoma  of  the  breast  is  extremely  rare  below  the  age  of  20  years  but,  thereafter,  the 
incidence steadily rises so that by the age of 90 years nearly 20% of women are affected.  
Gender 
Less than 0.5% of patients with breast cancer are male.
Genetic 
It occurs more commonly in women with a family history of breast cancer than in the general 
population.  Breast cancer related to a specific mutation accounts for about 5% of breast cancers, yet 
has far reaching repercussions in terms of counseling and attempted prevention in these women.  
Breast cancer syndrome
1. Li-Fraumeni syndrome
 P53 gene mutation
Autosomal dominant mutation
2. Cowden’s disease
Multiple hamartoma syndrome
Facial trichilemmoma, papilloma, bilateral breast cancer
3. Ataxia telangiectasia
Hemangioma breast cancer
Chromosomal Abnormalities
1. BRCA one gene mutation – Chromosome 17q
Poorly differentiated
Invasive ductal type
Hormone receptor negative
Associated with ovarian, prostate and colon cancers
2. BRCA-2  gene mutation – Chromosome 13 q
Well differentiated
Invasive ductal carcinomas
Express hormone receptors
Associated with ovarian, colon, prostate, pancreas, gallbladder, bile duct, stomach cancers and 
melanoma
3. HER-2  mutation (rbB2, transmembrane growth factor)
Invasive breast cancer ; upto 80% ductal carcinoma
Poor diagnosis
    4.  P 53 mutation
Associated with poor diagnosis
Resistance to chemotherapy
Diet
Because breast cancer so commonly affects women in the developed world, dietary factors may 
play a part in its causation.  There is some evidence that there is a link between diets low in phyto-
oestrogens.  A high intake of alcohol is associated with an increased risk of developing breast cancer.
Endocrine.
Breast cancer is commoner in nulliparous women and breast feeding in particular appears to be 
protective. Also protective is having a first  child at an early age, especially if associated with late 
menarche and early menopause.  It is known that in post menopausal women, breast cancer is more 
common in the obese.  This is thought to be because of an increased conversion of steroid hormones to 
oestradiol in the body fat.  The role of exogenous hormones, in particular the oral contraceptive pill and 
HRT, i9n the development of breast cancer is more controversial, but it can be said with some authority 
that for most women the benefits of these treatments will far outweigh the small putative risk.
Risk of developing breast cancer
The increase in the likelihood of developing breast cancer associated with the above risk factors 
is usually quantified in terms of the relative risk (RR).  Thus, an RR of 2.0 means that the individual 
has twice the chance of developing breast cancer as the average for the population, whereas an RR of 
0.5 indicates a risk reduction of 50%.
Pathology
Breast cancer may arise from the epithelium of the duct system anywhere from the nipple end 
of major lactiferous ducts to the terminal duct unit, which is in the breast lobule.  The disease may be 
entirely in situ, an increasingly common phenomenon with the advent of breast cancer screening, or 
may be invasive cancer.  The degree of differentiation of the tumour is usually described by three 
grades: well differentiated, moderately differentiated or poorly differentiated.  Commonly, a numerical 
grading  system  based  on  the  scoring  of  three  individual  factors  (nuclear  pleomorphism,  tubule 
formation and mitotic rate) is used. With grade III cancers roughly equating to the poorly differentiated 
group. 
Previously, descriptive terms were used to classify breast cancer (scirrhous, meaning woody, or 
medullary, meaning brain like). More recently, histological descriptions have been used.  These have 
been shown to have clinical correlations in the way the tumour behaves and are likely to be used for the 
near future.  However, with the increasing application of molecular markers, there will be a change and 
it is likely that much more information about an individual tumour will be routinely reported, such as 
its likelihood of metastasis and to which therapeutic agents it will be susceptible. 
Current nomenclature 
Ductal carcinoma is the most common variant, but lobular carcinoma occurs in up to 15% of 
cases.   There  are  subtypes  of  lobular  cancer  including  the  classical  type,  which  carries  a  better 
prognosis than the pleomorphic type.  Occasionally, the picture may be mixed with both ductal and 
lobular  features.   Rarer  histological  variants,  usually  carrying  a  better  prognosis,  included  colloid 
carcinoma, whose cells produce abundant mucin, medullary carcinoma with solid sheets of large cells 
often  associated  with  a  marked  lymphocytic  reaction  and  tubular  carcinoma.   Invasive  lobular 
carcinoma is commonly multifocal and/or bilateral. Cases detected via the screening programme are 
often smaller, better differentiated and of special type than those presenting to the symptomatic service. 
Inflammatory  carcinoma  is  a  fortunately  rare,  highly  aggressive  cancer  that  presents  as  a 
painful,  swollen  breast,  which  is  warm with  cutaneous  oedema.   This  is  due  to  blockage  of  the 
subdermal lymphatics with carcinoma cells. Inflammatory cancer usually involves at least one-third of 
the  breast  and  may  mimic  a  breast  abscess.  A  biopsy  will  confirm  the  diagnosis  and  show 
undifferentiated carcinoma cells.  Its used to be rapidly fatal with surgery only hastening the end nut, 
with  aggressive chemotherapy and radiotherapy with salvage,  surgery,  the prognosis  has improved 
considerably. 
In situ carcinoma is preinvasive cancer that has not breached the epithelial basement membrane. 
This was previously a rare, usually asymptomatic finding in breast biopsy specimens, but is becoming 
increasingly common owing to the advent of mammographic screening: it now accounts for over 20% 
of cancers detected by screening in the UK.  In situ carcinoma may be ductal (DCIS) or lobular (LCIS), 
the latter often multifocal and bilateral. Both are markers for the later development of invasive cancer, 
which will go on to develop in at least 20% of cases.  Although mastectomy is curative, this is over 
treatment in many cases and the best treatment for in situ carcinoma is the subject of a number of 
clinical trials.  DCIS may be classified by the Van Nuys system, which combines the patient’s age, type 
of DCIS and presence of microcalcification, extent of resection margin and size of diseases.  Patients 
with  a  high  score  benefit  from radiotherapy after  excision,  whereas  those  of  low grade,  who  are 
completely excised, need no further treatment.  
Staining for oestrogen and progesterone receptor (ER and PR) is now considered routine, as 
their  presence  will  indicate  the  use  of  adjuvant  hormonal  therapy  with  tamoxifen.   Increasingly, 
tumours  are  stained  for   C-erbB2  (a  growth  factor  receptor),  as  patients  can  be  treated  with  the 
monoclonal antibody against this receptor if they relapse.
The pathologist is an important member of the breast cancer team and will increasingly help 
decide which adjuvant therapies will be appropriate. 
Paget’s disease of the nipple 
Paget’s disease of the nipple (Fig.55.27a. and b.) is a superficial manifestation of an underlying 
breast  carcinoma.  It presents as an eczema-like condition of the nipple and areola, which persists 
despite local treatment.  The nipple is eroded slowly and eventually disappear.  If left, the underlying 
carcinoma will sooner or later become clinically evident.  Nipple eczema should be biopsed if there is 
any doubt about its cause.  Microscopically, Paget’s diseases is characterized by the presence of large, 
ovoid cells with abundant, clear, pale-staining cytoplasm in the Malpighian layer of the epidermis.
THE SPREAD OF BREAST CANCER.
Local spread
The tumour increases in size and invades other portions of the breast.  It tends to involve the 
skin and to penetrate the pectoral muscles and even the chest wall. 
Lymphatic metastasis
Lymphatic  metastasis  occurs  primarily  to  the  axillary  lymph  nodded  and  to  the  internal 
mammary chain of lymph nodes.  The site of the tumour within the breast does not dictate which nodes 
will be involved, for example medial tumours spread just as readily to the axillary nodes as do lateral 
tumours. The involvement of lymph nodes is not just a chronological event in the evolution of the 
carcinoma,  bit  rather  a  marker  for  the  metastasis  potential  of  the  tumour.  Involvement  of 
supraclavicular nodes and of any contralateral lymph nodes represents advanced disease. 
Spread by the bloodstream.
It is by this route that skeletal metastases occur,  although the initial  spread may be via the 
lymphatic system.  In order of frequency, the lumbar vertebrae, femur, thoracic vertebrae, rib and skull 
are affected and these deposits are generally osteolytic.  Metastases any also commonly occur in the 
liver, lung and brain and occasionally, the adrenal glands and ovaries, but have been described in most 
body sites. 
Clinical presentation 
Although any portion of the breast, including the axillary tail, may be involved, breast cancer is 
found most frequently in the upper, outer quadrant.  Most breast cancers will present as a hard lump, 
which may be associated with in drawing of the nipple.  As the disease advances locally there may be 
skin  involvement  with  peau  d’orange  or  frank  ulceration  and  fixation  to  the  chest  wall.   This  is 
described as cancer-en-cuirasse.  About 5% of breast cancers in the UK will present with either locally 
advanced disease or symptoms of metastatic disease.   This figure is nearer 20% in the developing 
world.  These patients must then undergo a staging evaluation so that the full extent of their disease can 
be  ascertained.   This  will  include  a  careful  clinical  examination,  chest  radiograph,  serum alkaline 
phosphatase and gamma-glutamine transaminase (GGT), with liver ultrasound if these are abnormal 
and  an  isotope  bone  scan.   This  is  important  for  both  prognosis  and  treatment:  a  patient  with 
widespread visceral metastases may obtain an increased length and quality of survival from systemic 
hormone or  chemotherapy,  but  she is  not  likely to  benefit  from surgery as  she will  die  from her 
metastases before local disease become becomes a problem.  In contrast, patients with relatively small 
(less than 5cm in diameter) tumours confined to the breast and ipsilateral lymph nodes rarely need 
staging  beyond  a  good  clinical  examination  as  the  pick-up  rate  for  distant  metastases  is  so  low. 
Currently, a chest radiograph, full blood count and liver function tests are all that are recommended for 
screening for patients with early-stage breast cancer. Phenomena resulting from lymphatic obstruction 
in advanced breast cancer.
Peau d’orange
Peau d’orange is due to cutaneous lymphatic oedema.  Where the infiltrated skin is tethered by 
the sweat ducts, it cann0t swell,  leading to an appearance like orange skin.  Occasionally the same 
phenomenon is seen over a chronic abscess.
Late oedema of the arm is a troublesome complication of breast cancer treatment, fortunately 
seen less often now that radical axillary dissection and radiotherapy are rarely combined.  However, it 
does still  occur occasionally after either modality of treatment alone and appears at any time from 
months to years after treatment.  There is usually no precipitating cause but recurrent tumour should be 
excluded as neoplastic  infiltration of the axilla can cause arm swelling due to  both lymphatic  and 
venous blockage.  This neoplastic infiltration is often painful due to brachial plexus nerve involvement.
An oedematous limb is susceptible to bacterial  infections following quite minor trauma and 
these require vigorous antibiotic treatment.  Antibiotics may need to be given for much longer than is 
normal  and patients  at  risk  of  infection  should  have  antibiotics  readily  available  in  order  to  start 
treatment promptly.  Treatment of late oedema is difficult but limb elevation, elastic arm stockings and 
pneumatic compression devices can be useful.
Cancer-en-cuirasse.
The skin of the chest is infiltrated with carcinoma and has been likened to a coat.  It may be 
associated  with  a  grossly  swollen  arm.   This  usually  occurs  in  cases  with  local  recurrence  after 
mastectomy, and occasionally is seen to follow the distribution of irradiation to the chest wall.  The 
condition may respond to palliative systemic treatment, but prognosis in terms of survival is poor. 
Lymphangiosarcoma 
Lymphangiosarcoma  is  a  rare  complication  of  lymphoedema  with  an  onset  many  years 
following the original treatment.  It takes the form of multiple subcutaneous nodules in the upper limb 
and must be distinguished from recurrent carcinoma of the breast.  The prognosis is poor but some 
cases  respond  to  cytotoxic  therapy  or  irradiation.   Interscapulothoracic  forequarter  amputation  is 
sometimes indicated. 
Staging of breast cancer 
There are two traditional systems of classification for breast carcinoma, which predominantly 
rely on clinical staging of the disease. These are the Manchester system and the International Union 
Against Cancer  TNM (tumour, nodes, metastases)staging system. 
Stage Tumour 
grade
Clinical extent Node 
grade
Clinical
extent
Distant metastases
TIS TIS No palpable 
tumour
N0 No nodal 
metastases
M0 = No known 
distant metastases
I T1 <2 cm N0 No nodal 
metastases
II T2 2-5 cm N1 Mobile axillary 
nodes
IIIa T3 >5 cm N2 Fixed axillary 
nodes
IIIb T4 Any size 
invading skin & 
or chest wall
N3 Supraclavicular 
ipsilateral nodes
IV Any T Any N M1= distant 
metastases
The TNM system was an attempt to allow a common language among oncologists worldwide, 
thus  allowing  accurate  information  exchange  and  evaluation  of  studies  of  treatment,  as  well  as 
providing  prognostic  information  to  aid  in  the  planning  of  treatment  for  the  individual  patient. 
However, this refinement of taxonomy in fact contributes little to any of these activities. 
Further subdivisions in the TNM system now mean that there are seven T-Stages, four N-stages 
and three M-stages, allowing for 180 possible combinations.  Pathological lymph node staging depends 
on both the number of lymph nodes  removed,  thus  the extend of surgery,  and how assiduous the 
pathologist  is  in  looking  for  deposits  of  tumour  within  thee  nodes.  ‘M’  staging  depends on  what 
investigation have been performed, thus will vary between centres.  Consequently staging is observer 
biased.
Although prognosis broadly correlates with stage, other factors also influence prognosis and 
should be assessed, for example the Nottingham Prognostic Index includes not only tumour size and 
lymph node status but also tumour grade.  This has been validated in many centres and consists of a 
score given by the formulae I= (0.2x size) + grade + nodes.  The size is in centimeters, the grade is on a 
1-3 score and the nodes are also scored on 1-3 where a score of one indicates no nodal involvement, 
two indicates on e the there nodes involved.  Based on the overall index, patients can be divided into an 
excellent prognosis group, a moderate prognosis group and a poor prognosis group.  The chance of 
dying from breast  cancer in  the first  group is  so low that many patients  do not require additional 
treatment.
Conventional staging will indicate broadly which treatment is required but again other factors 
may be equally important.  For example, surgical treatment of a small stage I or II (T1or T2) breast 
tumour usually requires only wide local excision rather than mastectomy, but the latter may have to be 
performed if  the  breast  is  very small,  the  tumour  central  or  multifocal,  or  for  patient  preference. 
Equally, the use of adjuvant systemic therapy is decided not only on tumour size and lymph node status 
but  also  biological  measures  such  as  oestrogen receptor  status,  patient  age  and menopausa  status. 
Tamoxifen can be recommended irrespective of clinicopathological variable if the patient is hormone 
receptor positive. 
Thus, as we gain more knowledge of the biological variables that affect prognosis, it becomes 
increasingly clear that  it  is  these factors (discussed in  more details  below),  rather than anatomical 
mapping, which influence outcome and treatment.  Perhaps a more pragmatic approach would be to 
classify patients according to the treatment that they require. 
Pragmatic classification for breast cancer
Group Approximate
5–year survival
Example Treatment
‘very-low-risk primary 
breast cancer
>90% Screen-detected DCIS, 
tubular or special types
Local
‘Low-risk primary 
breast cancer
70-90% Node negative with 
favourable histology
Locoregional with/
without systemic
‘High-risk primary 
breast cancer
<70% Node positive with 
unfavourable histology
Locoregional with 
systemic
Locally advanced <30% Large primary or 
inflammatory
Primary systemic
Metastatic - - Primary systemic
Prognosis of breast cancer 
The best indicators of likely prognosis in breast cancer are still tumour size and lymph node 
status.  However, it is realised that some large tumours will remain confined to the breast for decades, 
whereas some very small tumours are incurable  at diagnosis.  Hence the prognosis of a cancer depends 
not on tis chronological age but on its invasive and metastatic potential.  In an attempt do define which 
tumours  will  behave  aggressively,  and  thus  require  early  systemic  treatment,  a  host  of  prognostic 
factors has been described.  These include histological grade of the tumour, hormone receptor status, 
measures of tumour proliferation such as S-phase fraction and thymidine labeling index, growth factor 
analysis and oncogene or oncogene product measurements.  Many other are under investigation but 
have proved of little practical value in patient management. 
Sentinel lymphnode Biopsy :
Sentinel lymphnode biopsy, or sentinel lymph node dissection (SLND), was adapted to breast 
cancer in the early 1990s after the successful application of similar technique to melonama.  Vital dye 
and / or radio labeled colloid is injected into the parenchyma immediately surrounding a primary breast 
cancer or in a subareolar manner.  The mapping agent is then used to follow the path of lymphatic 
drainage to sentinel lymphnodes (SLNs), the first nodes encounter by tumour cells as the metastasize to 
the axilla.  The pathologic status of axillary sentinel lymphnode is therefore, representative of the entire 
axillary basin, with tumour negative SLNs predicting that nonsentinel nodes will also be tumour free. 
On the other hand, tumour positive SLNs indicate possible metastasis to nonsentinel nodes in the same 
drainage basin and usually warrant additional surgical interventions.
Although  axillary  lymphnode  dissection  (ALND)  is  highly  accurate,  it  carries  a  risk  of 
significant complications.  SLND is much less invasive than ALND but provides the same staging 
information with more accuracy and less morbidity.  Numerous studies have demonstrated the accuracy 
of SLND in breast cancer, with SLN idenfication rates of 95% or higher and false negative rates of less 
than 5%.
Indication for SLND :
  Early invasive breast cancer who presents without clinically palpable axillary nodes, including 
patients who have undergone previous excisional biopsy.
Two mapping agents :
1. (a) Vital blue dye (Isosulfan)   (b)  Metheline blue
2.  Technetium labeled sulphor colloid use with gamma probe
Site of Injection :
Peritumoral, subareolar, combined
LITERATURE REVIEW OF SENTINEL NODE BIOPSY 
The axillary nodal status is accepted universally as the most powerful prognostic tool available 
for early stage breast cancer.  Breast cancer patients routinely undergo surgical staging of the axilla 
because other primary tumor features are inadequate in predicting the presence versus absence of nodal 
positivity.  The status of the axillary lymph nodes also guides treatment options and adjuvant therapies. 
The  removal  of  level  I  and level  II  lymph nodes  at  axillary node  dissection (ALND) is  the most 
accurate  method to  assess nodal  status,  and it  is  the universal  standard.  ALND is associated with 
several  adverse  long-term sequelae  including  lymphedema,  the  disruption  of  nerves  in  the  axilla, 
chronic shoulder pain, weakness, and joint dysfunction. Additionally, the survival advantage of ALND 
has been challenged, and less morbid methods of evaluating the axillary nodal basin have been sought.
Breast cancer spreads from the tumor bed to one or a few lymph nodes before it spreads to other 
axillary nodes.  These sentinel nodes can be identified and surgically excised for histological analysis. 
Lymphatic mapping with sentinel lymph node biopsy (SLNB) has emerged as an effective method of 
detecting axillary metastases.   Veronesi and colleagues  randomly assigned 516 women with early 
stage  breast  cancer  to  either  SLNB and ALND or  SLNB alone  (ALND) was  performed only for 
axillary metastases in the SLNB-alone arm).  The authors demonstrated that SLNB was accurate and 
reliable with false-negative rate of 80%.  There Was Less Pain and better arm mobility in those who 
underwent  SLNB only.   Additionally,  there  were no differences  in  local  recurrence  or  survical  at 
follow-up.   The  NSABP-32 trial  is  the  largest  multicenter  trial  to  date  examining  the  safety  and 
accuracy of SLNB.  The trial  randomly assigned women with clinically negative axilla  to  receive 
SLNB with an ALND or SLNB alone.  Early results have demonstrated that SLNB is safe and reliable, 
with false-negative rates of 8% to 10%, and lower morbidity that  ALND. Although the long term 
results are forthcoming, the clinical advantages of SLNB are apparent, and the procedure is becoming 
the preferred standard by patients and breast cancer surgeons. 
Given the  rapid  growth  of  lymphatic  mapping and SLNB, surgical  groups  have  developed 
several  variations  in  practice,  and  many  technical  aspects  of  the  procedure  are  evolving.   These 
variations have included the choice of mapping label.   Radioisotope quantity and processing,  label 
injection  site,  timing  of  radioisotope  injection,  and  the  use  of  preoperative  lymphoscintigraphy 
scanning. Because these controversies have not been studied extensively in clinical trials.  The method 
of lymphatic mapping ultimately should be selected based on those method that have been proven safe, 
and on the services and resources of a given breast care program.   
Radioisotope alone
Krag and colleagues  first described the use of radioisotope alone for breast cancer in 1993, 
using technetium-99m sulfur colloid and a hand-held gamma probe.  The sentinel node identification 
rate was 98%, with a false-negative rate of 11%.  Technetium-99m sulfur colloid is the most widely 
used radioisotope for lymphatic mapping in the United States.  In Europe, technetium 99m-colloidal 
albumin is used most.  The specific radioisotope selected for the mapping process is determined largely 
by availability and by the center’s nuclear medicine practices.  The doses of radioactive technetium 
vary by institution and range from 0.1 to 4mCi.
Blue dye
Isosulfan blue dye (Lymphazurin 1%, US Surgical Corp, Norwalk, CT) initially was studied 
extensively in lymphatic mapping for melanoma.  The use of isosulfan blue dye as a single agent in 
SLNB  for  breast  cancer  initially  was  reported  by  Giuliano  and  colleagues,  with  sentinel  node 
identification rates of 98%, without false-negative nodes.  The major disadvantage of isosulfan blue 
dye is the risk of life-threatening allergic and anaphylactic reactions. The reported allergic reaction rate 
ranges from 1% to 3%.  Most reactions consist of urticaria, rash, blue hives, and pruritus. Although 
rare, anaphylaxis and hypotension also have been reported.  Overall, isosulfan blue dye has excellent 
results for lymphatic mapping in breast cancer, and is the blue dye most commonly used.
Methylene blue also has been successful in SLNB for breast cancer. Simmons and colleagues 
identified the sentinel node in approximately 93% of patients studied in a cohort of more than 100 
patients.  Concordance with radioisotope was observed in 95%.
Additionally, methylene blue was compared with Isosulfan blue dye by blessing and colleagues 
in 2002. The authors found that all patients had high concomitant isotope mapping and similar sentinel 
node identification rates.  Methylene blue is preferred by some authors because of its lower costs, and 
also  because  of  its  lower  risk  of  allergic  reactions.   Methylene  blue  must  be  injected  in  the 
subcutaneous  tissues:  inadvertent  injection  into  the  dermis  has  resulted  in  severe  skin  reactions 
including necrosis and dermolysis.
Combination of blue dye and radioisotope 
Several  authors  have  demonstrated  that  the  combination  of  radioisotope  and  blue  dye  for 
lymphatic  mapping  improves  the  sentinel  lymph  node  (SLN)  identification  rate.   Albertini  and 
colleagues first reported the successful use of lymphatic mapping with both blue dye and radioisotopes 
prospectively.   The  results  have  been  confirmed  with  several  studies  demonstrating  that  the 
combination method improves the sentinel node identification rate, and dual-agent lymphatic mapping 
has been accepted universally. Some centers have elected to rely on radioisotope mapping alone, given 
the potentially life-threatening allergic reactions of isosulfan blue dye.
Filtered versus unfiltered radioisotope 
Identification of a radioactive lymph node depends upon adequate uptake of the radioisotope 
from the breast  parenchyma by intramammary lymphatics.   The radioisotope must travel  from the 
breast to the sentinel node in a timely fashion. Radioisotope uptake and travel times ultimately depend 
on the size of the labeled carrier and on the amount of carrier fluid used.  Large particles may not 
migrate to regional nodes at all (those greater than 400nm) and those too small may migrate too quickly 
to  the  entire  nodal  basin  making  identification  of  single  sentinel  nodes  difficult.   The  size  of 
technetium-99 sulfur colloid may be altered by the selective use of filters and the pore size of filters 
used.  Filtration through 100 or 220 nm filters has been studied, with goals of particle size ranging from 
50  to  200  nm.  Filtered  preparations  resulting  in  smaller  particles  travel  more  quickly  and  may 
potentially  reach  more  SLNs  including  the  higher  echelon  nodes,  if  there  is  a  prolonged  interval 
between injection of radioisotope and surgery.  The unfiltered colloid may be less likely to travel to 
higher echelon nodes, given its larger size and slower transit time.  Linehan and colleagues  compared 
the success of SLNB using filtered versus unfiltered technetium-99m sulfur colloid combined with blue 
dye mapping.  Although the authors found no difference in the overall SLN identification rate, there 
were significantly more SLNs that were radioactive in the unfiltered group versus the filtered group 
(88% versus 73%; P=.03).  These results suggest that filtered smaller particles may pass too quickly 
from the injection site through the nodal basin before the sentinel nodes are removed.
There has been no consensus on the use of filtered versus unfiltered radioisotopes for lymphatic 
mapping in breast cancer.  The various features may be considered advantages or disadvantages, and 
selection depends upon the timing of surgery in relation to injection times. 
Injection site for mapping agents
Peri-tumoral injection 
In efforts to replicate the intramammary lymphatic pathways that may have been traversed by 
metastases, the initial data regarding SLNB used peri-tumoral injections of the mapping agents.  For 
patients who have nonpalpable tumors, this method has proven difficult and time-consuming, because 
it requires the use of additional imaging modalities to guide the peri-tumoral injection of radioisotopes. 
Peri-tumoral injections also have a higher potential for shine through, where residual radioactivity from 
the peri-tumoral injection site creates misleading background activity detected by the gamma probe 
from the axilla.  It is for these reasons that alternate injection sites have been pursued.
Subareolar and dermal injection 
Mammary lymphatics develop as radial extensions from the nipple breast bud.  Nearly all breast 
tissue lymphatic drainage passes through the subareolar plexus of Sappey and then into the axillary 
nodal  basin;  hence  dermal  and  subareolar  injections  are  potential  approaches  for  the  injection  of 
mapping  agents.   The  sites  are  particularly  advantageous  for  patients  who  have  non-palpable  or 
multicentric tumors; they also eliminate the shine through effect.
A potential disadvantage to subareolar and dermal injections is that up to 10% of breast cancer 
may demonstrate nonaxillary lymphatic drainage with sentinel nodes found in the internal mammary or 
supraclavicular nodal basins; hence not all breast tumors will have the same drainage patterns as the 
overlying skin and nipple areas.  Additionally, subareolar and dermal injection of blue dye may cause 
considerable postoperative discoloration of the breast (blue breast), which may last for several months.
Veronesi  and  colleagues  first  described  subdermal  injections  of  technetium  -99m  labeled 
albumin into the  dermis  overlying the  tumor  of  163 patients  undergoing SLNB and ALND.  The 
authors found that the SLN identification rate was 98% with a false-negative rate of 4.7%. Several 
authors have confirmed the reliability of dermal injections by direct comparisons between peri-tumoral 
and  skin  radioisotope  injections.   Borgstein  and  colleagues   studied  33  breast  cancer  patients 
undergoing lymphatic mapping, consisting of dermal injections of blue dye and peri-tumoral injections 
of radioisotope.  The authors found 100% concordance between blue and radioactive SLNs in 30 of the 
33  patients  studied,  without  any  false  negatives.  Linehand  and  colleagues  studied  200  patients 
undergoing SLNB with peri-tumoral or excisional biopsy site blue dye injections.  In the study, half of 
the  patients  also  received  Tc99-sulfur  colloid  injected  peri-tumorally,  and  the  other  half  received 
radioisotopes by means of dermal injections.  The SLN identification rates were 92% for those patients 
receiving  intraparenchymal injections of both blue dye and radioisotopes.  For those patients receiving 
intraparenchymal injection of blue dye and dermal injection of radioisotopes, the SLN identification 
rate was 100%.  In both subsets  of patients, the concordance between blue-stained and radioactive 
sentinel nodes was also high (97% and 95%, respectively).  Those patients receiving dermal injections 
of radioisotopes had a greater proportion of sentinel nodes radioactive when compared with the group 
receiving peri-tumoral  injection of  radioisotopes  (97% versus 78%; P<.001).   A subsequent  report 
compared 134 patient receiving intraparenchymal lymphatic mapping with 164 patients with mapping 
using intraparenchymal blue dye and dermal injection of radioisotopes. The SLN identification rate was 
significantly higher in the group receiving dermal injections of radioisotopes (98% versus 89%).  There 
was no difference in the false-negative rates (4.4% and 4.8)
Several  authors  have  studied  the  differences  between  lymphatic  drainage  pathways  of 
intradermal  versus  intraparenchymal  injections  of  radioisotopes.  Shen  and  colleagues  studied  the 
preoperative lymphoscintigraphy scans of 30 patients undergoing lymphatic mapping for cutaneous 
breast melanomas and 97 patients undergoing lymphatic mapping with peri-tumoral injection for breast 
cancer.   The  authors  found  that  there  were  a  higher  percentage  of  nonaxillary  SLNs  in  the 
melanoma/dermal  injection  group (26% versus  5%).   In  the  melanoma cases,  there  were  bilateral 
axillary and supraclavicular drainage sites detected, whereas the breast cancer cases mapped to the 
ipsilateral axillae.  The results demonstrated that axillary drainage patterns varied between peri-tumoral 
and dermal lymphatics.  Additionally, given the importance of the ipsilateral axillary, mammary, and 
supraclavicular nodal basins in the staging of breast cancer, if drainage to these sites can be detected 
with dermal injection, the dermal route may be adequate for the staging of breast cancer. 
Klimberg  and  colleagues  compared  lymphatic  mapping  using  subareolar  injections  of 
radioisotope to peri-tumorally injected blue dye.  The authors found successful mapping in 64 of 68 
patients studied (94%).  The SLN identification rate for blue dye was 89.9% versus an identification 
rate of 94.2% for radioisotope.   In the study,  all  blue nodes were also radioactive,  indicating that 
subareolar injection did not miss any axillary SLNs using this method of mapping. 
Subareolar and dermal injection sites also have been examined using various areas of the breast 
for injection.  Beitsch and colleagues studied subareolar radioisotope injected into the mirror-image 
quadrant of the nipple-areolar tissue and peri-tumoral blue dye injections.  The SLN identification for 
blue dye and radioisotopes were 94% and 99%, respectively, and 99% of the blue SLNs were also 
radioactive. Kern  reported successful results of lymphatic mapping using subareolar injections of blue 
dye and radioisotopes at the upper, outer aspect of the nipple-areolar tissue. 
Although  SLNB  has  proven  reliable  in  women  who  have  unifocal  disease,  the  studies 
examining the ideal injection site have set the stage for the consideration of SLNB in multicentric and 
multifocal  disease.   Tousimis  and  colleagues   reported  results  from the  largest  series  examining 
lymphatic mapping in multicentric and multifocal breast cancer. The authors examined 70 patients who 
underwent  mapping using a combination of radioisotopes  and blue dye.   In the study,  63 patients 
received a single intradermal injection of radioisotopes directly over the largest tumor, and five patients 
received radioisotope peri-tumoral radioisotope injections.  Additionally, 67 patients received a single 
intraparenchymal blue dye injection adjacent to the supero-lateral side of the largest invasive tumor or 
biopsy cavity.  The authors found that the accuracy (SLN identification rate of 96%) and false-negative 
rate (8%) of SLNB in patients who had multicentric and multifocal breast cancers were comparable to 
those with unifocal tumors. Though confirmatory studies are warranted, these results demonstrate the 
feasibility of SLNB in patients who have multicentric and multifocal breast cancer.
Preoperative Lymphoscintigraphy
Patients undergoing lymphatic mapping with radioisotopes most often receive a preoperative 
lymphoscintigram (PL) to aid in SLN identification.  PL typically consists of anterior and lateral views 
and specific patient positioning to optimize transit time and radioisotope drainage.  Scanning routinely 
is initiated 20 minutes after radioisotope injection, and images are repeated until the primary SLN basin 
is identified and there is adequate uptake.  The patient then is taken to the operating room for SLNB.
It is controversial whether preoperative scanning is of diagnostic value.  Many authors have 
examined  the  accuracy  of  the  PL,  and  given  the  additional  time  and  cost,  question  its  value  in 
improving the identification of sentinel lymph nodes.  Proponents of the technique have argued that the 
scan may guide the timing of surgery when radioisotope injection is performed on the same day as the 
operation.  Additionally, PL with identify the primary drainage pattern, and also internal mammary 
(IM) sentinel  nodes.   There  is  no consensus  regarding  the  management  IM SLNs that  have  been 
identified by PL, and current recommendations for adjuvant therapies have been defined mostly by 
axillary nodal metastases.  McMasters and Colleagues evaluated the role of PL in breast cancer.  In the 
study, a PL was performed in 348 of 588 patients (59%), and 240 patients did not receive scans.  The 
SLN was identified in 221 of the 240 (92%) patients who did not undergo preoperative scanning.  In 
these  patients,  the  false-negative  rate  was  1.6%.   In  those  patients  receiving  a  preoperative 
lymphoscintigram.  The SLN was identified in 310 of the 348 (89.1%) patients, with a false-negative 
rate of 8.7%.  The authors found no significant difference in the SLN identification rate, false-negative 
rate, or number of SLNs removed between patients receiving PL and those proceeding to operation 
without scanning.  Borgstein and colleagues  also studied the role of PL in breast cancer patients. The 
authors found that the intraoperative gamma probe was more sensitive in detecting radioactive nodes in 
the axilla than the PL, even when delayed images were obtained.  In the study, axillary accumulation 
was absent in 14 of 130 patients receiving PL.  The intraoperative gamma probe was unsuccessful in 
detecting radioactivity in 8 of 130 cases (seven of these patients also had negative PL).
Data have continued to emerge questioning the ability of PL to improve the accuracy of SLNB, 
and some centers have abandoned the technique, focusing only on resecting SLNs in the axilla, and 
relying on the intraoperative gamma probe to detect radioactive SLNs.  Until there are definitive data 
regarding the treatment and importance of nonaxillary drainage, the decision to use PL is ultimately the 
decision of the surgeon and the multidisciplinary breast team.
Timing of radioisotope injection 
Lymphatic mapping with radioisotopes is performed either as a 1-or 2- day procedure.  The 
half-life of technitium-99 is approximately 6 hours and must be taken into account when planning 
SLNB.
The single –day procedure requires breast injection on the morning of surgery, followed by 
serial imaging at 1 to several hours after injection until the SLN is identified. In some cases, the process 
can take several hours and may significantly delay the operation.  The effect of delay on patients and 
on operating room scheduling has led some centers to use a 2-day mapping procedure, with injection of 
radioisotopes 1 day before operation.  The 2-day procedure has been criticized because of the concern 
that it may require higher doses of radioisotopes or that with prolonged exposure, radioisotopes may 
move into higher-echelon nonsentinel lymph nodes. Winchester and colleagues  evaluated lymphatic 
mapping with  radioisotope  injection  1 day before  operation.   The  study consisted  of  180 patients 
receiving  lymphatic  mapping  and  SLNB,  with  technitium-99  sulfur  colloid  injected  1  day 
preoperatively.   The  authors  found that  the  SLN identification rate  was  90%, and was influenced 
largely by the surgeon’s learning curve. Additionally, mapping was improved when 1.0 mCi-filtered 
radioisotope was used (versus 0.5 to 1.0 mCi unfiltered radioisotope). McCarter and colleagues  also 
had successful outcomes using the 2-day procedure.  The authors studied 933 patients who received 0.1 
mCi of dermal technitium-99 sulfur colloid in 0.05 cc normal saline on the day of surgery, and 387 
patients  who  received  0.5  mCi  technitium-99  sulfur  colloid  dermal  injections  on  the  day  before 
operation.   All  of  the  patients  had peri-tumoral  blue  dye  injections  intraoperatively.   The  median 
number of SLNs identified in he of isotope counts was similar between the two groups.  Likewise, 
Solorzano and colleagues  reported success with the 2-day lymphatic mapping technique.  The authors 
found that injection of 2.5 mCi technetium sulfur colloid (filtered) peri-tumorally on the day before 
surgery with lymphoscintigraphy to track drainage resulted in an overall SLN identification of 97.5%. 
All positive SLNs with blue dye staining were also radioactive.  Based on the current literature, a 2-day 
lymphatic mapping procedure is safe and reliable for SLNB in breast cancer.
Should axillary dissection remain the standard of care in patients with positive sentinel lymph 
nodes?
Morbidity associated with axillary lymph node dissection 
ALND  has  been  associated  with  a  significant  risk  of  lymphedema,  sensory  disturbances, 
shoulder dysfunction, wound infection, and incisional pain.   ALND patients face a lifelong risk of 
lymphedema that ranges from 10% to 50% depending on other risk factors, duration of follow-up and 
method of detection.  Recent data from two very large multicenter trials provide initial reports on the 
morbidity associated with SLN biopsy as opposed to ALND.  Among all examined variables, patients 
undergoing SLN biopsy fair better than patients undergoing completed axillary evaluation.
Nonsentinel node metastases 
With improvements in breast cancer screening and increased public awareness, an earlier stage 
distribution for breast  cancer  and a  lower incidence of axillary metastases  are  starting to  be seen. 
Recent estimates suggest that only 30% of patients have evidence of axillary metastases at the time of 
diagnosis.  Studies of patients undergoing SLN biopsy with a concomitant ALND have demonstrated 
that axillary metastases will be limited to the SLN in 30% to 67% of cases.  Several other authors have 
confirmed that roughly 50% of patients who have positive SLNs subsequently are found to have no 
evidence  of  further  axillary  disease.  Removal  of  negative  nodes  does  not  provide  any significant 
benefit, yet  a fair number of patients with metastases isolated to the SLN still will be subjected to 
ALND and all of its associated morbidity to have definitive proof of their node-negative status. There 
is  clearly no benefit  to removing negative axillary nodes, and when residual metastases do extend 
beyond the SLN, chemotherapy has been shown to sterilize 23% of axillary metastases.
From  1995  to  1999,  Calhoun  and  Colleagues   identified  634  breast  cancer  patients  who 
underwent SLN biopsy.  SLNs were scrutinized further using immunohistochemistry if hematoxylin 
and eosin evaluation was negative, and ALND was recommended for patients who had SLN biopsies 
positive by immunohistochemistry (IHC).   Seventy-eight  patients  (12.3%) with IHC-positive SLNs 
were offered ALND.  Sixty-one consented, whereas 17 refused.  Fifty-eight (95.1%) had negative non-
SLNs.  Three (4.9%) had non-SLN metastases: one (1.6%) had macrometastatic disease, whereas two 
(3.3%) had micrometastases.  Among patients with SLNs positive by IHC only, there were no axillary 
recurrences after  a mean of 80.5 months.   When ALND was performed in the setting of an IHC-
positives SLN, 1.6% of non-SLNs harbored macrometastases, and 3.3% had micrometastases. When 
ALND was not performed, axillary recurrence was no seen.  The reported low risk of non-SLN disease 
in this setting provides further evidence in support of avoiding ALND for SLNs positive by IHC only.
On the contrary, according to Menes and Colleagues, who examined the nonsentinel nodes in 
124  SLN-positive  patients,  nonsentinel  node  metastases  were  found  in  19% of  patients  who  had 
sentinel node metastases less than 0.2mm, 20% of patients who had SLN metastases measuring 02.mm 
to 2mm, and 46% of patients who had metastases greater than 2mm.  This dataset demonstrates that in 
patients  who  are  considered  SLN-negative  (metastases  <.2mm)  and  in  those  who  have 
micrometastases, omitting an axillary dissection may leave residual axillary disease in 20% of cases.
The discordant findings noted in these two studies provide further evidence that conclusive, 
prospective, long term data from multicenter trials evaluating issues specific to SLN biopsy is well 
awaited. 
Survival impact 
Other data to support avoiding ALND in SLN-positive patients comes from important clinical 
trails.  During the 1970s,  as part  of the NSABP B-04 study,  clinically node-negative patients  were 
randomized to three treatment arms: radical mastectomy, total mastectomy with radiation, and total 
mastectomy  with  axillary  observation.   Regardless  of  the  type  of  axillary  management  received 
(axillary lymph node dissection in the radical mastectomy group, radiation alone in the second group, 
or observation with delayed intervention in the third group), the overall survival was equivalence.  This 
outcome equivalence has persisted on 25 years follow-up.  These historical data from NSBP B-04 
suggest that prophylactic resection of occult axillary metastases is comparable, in terms of survival, to 
axillary observation and delayed therapeutic ALND in cases of regional failure.  NSABP B-04 suggests 
that ALND is unlikely to confer a survival benefit.  Despite these findings, ALND has remained an 
essential component of breast cancer management 
Accrual to this phase III clinical trial was completed in an era of surgical treatment alone for 
breast  cancer  management,  before  the  advent  of  effective  systemic  therapy  for  breast  cancer. 
Subsequently,  axillary nodal status became the most powerful determinant of magnitude of benefit 
from adjuvant systemic therapy.  This remained true for several years while the adjuvant therapies for 
breast  disease  have  continued  to  evolve.   Decisions  regarding  additional  therapy  are  now  less 
dependent on the status of the axilla.  Unfortunately, the B-04 study was not powered statistically to 
address the survival benefits  of ALND; it  was designed to evaluate the overall  safety of modified 
surgical  strategies  (radical  mastectomy  versus  total  mastectomy  versus  total  mastectomy  and 
locoregional irradiation) as treatment for operable breast cancer.  Thus critics continue to argue that 
locoregional control may provide some benefit in terms of survival.
Local recurrence:
When scrutinized further, NSABP B-04 data provide information regarding axillary recurrence. 
In the radical mastectomy group, 40% of the patients were found to have positive axillary lymph nodes, 
with  the  axillary  recurrence  rate  approaching  approximately  1%.   Assuming  equal  randomization 
between the three treatment arms, one can deduce that approximately 40% of the patients in each group 
possessed  axillary  metastases.   Within  the  group of  patients  treated  with  total  mastectomy alone, 
without a specific axillary intervention, however, only 18.6% developed an axillary relapse as an initial 
treatment failure.  As suggested by the NSABP B-04 study, clinically occult and untreated axillary 
metastases  will  progress  into  clinically  evident  disease  requiring  a  delayed/therapeutic  ALND  in 
approximately  half  of  cases,  and  this  outcome does  not  appear  to  adversely affect  survival  when 
compared  with  patients  whose  axillary  disease  was  detected  by  a  staging  ALND  at  the  time  of 
diagnosis.
Axillary recurrence after a level I or II axillary dissection is unusual, occurring in 0.5% to 3% of 
patients  in  the  literature.  More  recently,  several  investigators  have  explored  the  rate  of  axillary 
recurrence after  SLN biopsy.   Since its  introduction,  the technique of SLN biopsy has evolved to 
optimize detection of axillary disease with false-negative rates approaching 5%.  Given this, one might 
expect a rate of axillary relapse or distant recurrence greater than or equal to 5%.  This is not the case, 
however, according to contemporary reports.
Jeruss  and  colleagues  presented  follow-up  data  on  864  patients.  Of  the  633  SLN-negative 
patients, 4.7% underwent completion ALND, while the remaining patients were observed.  Only two 
(0.32%) SLN-negative patients developed recurrence within the axilla: one of which had undergone 
completion ALND. Sixty-eight percent of the SLN-positive patients were managed with ALND, while 
32% were observed over a median follow-up of 27.4 months.  There were no recurrences among the 
SLN-positive group.  None of the study participants received radiation therapy with additional fields to 
include the axilla.  They compiled 10 published reports of axillary relapse after sentinel node biopsy 
and calculated an overall recurrence rate of 0.4% suggesting that axillary observation may be a feasible 
alternative in cases of both negative and positive SLNs.  Similarly, a pooled analysis by Smidt and 
colleagues  evaluated over 3000 patients with a median follow-up of 25 months resulting in an axillary 
recurrence rate of 0.25% in SLN-negative patients.  This included information from their own dataset, 
in which they encountered two patients who had axillary recurrence, representing 0.46% of the study 
population.
The Memorial Sloan Kettering group reported an overall rate of axillary recurrence of 0.25% 
after SLN biopsy.  Only 10 axillary relapses were identified among all 4008 patients.  Among 2340 
SLN-negative patients treated without ALND, only three recurrences were seen, corresponding to a 
0.12% axillary recurrence rate, providing further evidence that it is safe to omit ALND after a negative 
SLN.  The local  recurrence rates  after  positive SLN biopsy treated with and without  ALND were 
0.35% and 1.4%, respectively,  in  their  opinion,  the  rarity of  axillary recurrence after  SLN biopsy 
confirms that SLN biopsy is at least equivalent to ALND in regards to staging the axilla and achieving 
local control of axillary disease.
Badgwell  and  colleagues  at  Ohio  State  University  retrospectively  reviewed  patterns  of 
recurrence after SLN biopsy in 222 patients with a minimum of 24-month follow-up.  Of 159 SLN-
negative patients, five (3%) developed recurrences.  One had local (breast) recurrence, and four had 
distant recurrences.  There were no isolated regional (axillary) recurrences within the SLN-negative 
group.   Among SLN-positive patients,  the overall  recurrence rate  was 9.5%, with three local,  one 
regional,  and  two  distant  recurrences.  The  complete  absence  of  axillary  relapse  among  the  SLN-
negative patients is comparable to an early prospective observational study by Giuliano and colleagues, 
in which no local, regional, or distant recurrences were noted among 67 SLN-negative patients, with a 
median follow-up of 39 months.  After an extensive review if the literature, Newman  reported upon 10 
studies evaluating patients with negative SLNs treated without ALND.  This report yielded results from 
10 studies published between 2000 and 2005 in which the rate of axillary recurrence ranged from 0% to 
1.4% over the course of 26 to 39 months. 
Fewer studies have focused their evaluation on he rates of axillary and systemic failures after 
positive SLN biopsy.  Published results from the John Wayne Cancer Institute in 2003 describe the 
outcome of 46 SLN-positive patients treated without completion ALND based on patient preference or 
increased operative risk.  The degree of sentinel node disease ranged from cellular metastases in 50%, 
micrometastases in 35%, to macrometastases in the remaining 15% of study patients.  After a mean 
follow-up of 32 months, zero axillary recurrences were identified, and one systemic recurrence was 
identified.   Again,  Newman  reported  the  results  of  five  separate  studies  evaluating  the  axillary 
recurrence rates among SLN-positive patients treated without SALND published between 2003 and 
2005.  The axillary recurrence rate ranged from 0% to 2.6% with average follow-up raging from 25 to 
32 months.
Again, this is further evidence in favor of the SLN’s ability to accurately stage the axilla.  The 
results  of  several  major  clinical  trials  evaluating  multiple  long term outcome variables  after  SLN 
biopsy are anticipated however.
American College of surgeons Oncology Group Z0010 trial
The American College of surgeons Oncology Group Z0010 trial
 was designed to evaluate the prevalence and significance of micrometastases within the sentinel node 
and bone marrow of T1 and T2 breast cancer patients, and determine the rate of regional recurrence in 
patients with negative SLNs by hematoxylin and eosin staining.  Between 1999 and 2003, over 5500 
patients were enrolled.  In this prospective, single-arm, observational study, clinically node-negative 
patients undergoing breast conservation therapy and SLN biopsy also were subjected to bilateral bone 
marrow  biopsy.   ALND  was  performed  in  cases  of  SLN  failure.   SLNs  deemed  negative  by 
hematoxylin  and eosin  (H&E) were sent  to  a  core laboratory for  immunohistochemical  evaluation 
along with bilateral bone marrow aspirates.  Patients who had one or two positive SLNs were then 
eligible for randomization in ACOSOG Z0011.  Completion ALND was required for patients who had 
three or more positive SLNs, and for patients with one to two positive SLNs who did not consent to 
ACOSOG  Z0011.   Postoperatively,  these  patient  were  to  receive  whole-breast  radiation  without 
additional  fields  to  include  the  supraclavicular  lymph  nodes.   Adjuvant  systemic  therapy  was 
recommended for all patients with SLNs positive by H&E. Primary and secondary endpoints included 
overall  survival,  disease-free  survival,  and  axillary  recurrence.  In  addition  to  determining  the 
prevalence and prognostic significance of micrometastases detected by IHC, investigators also hope to 
glean some evidence regarding the rate of axillary recurrence in patients whose nodes are negative by 
H&E staining. 
The first available published data from this trial report the surgical complications associated 
with SLN biopsy in 5327 patients.  SLN metastases were identified by H&E staining in 24% of the 
study populations.  Patients  who subsequently underwent ALND were excluded from the analysis. 
Early complications such as anaphylaxis (0.1%), brachial plexus injury (0.2%) wound infection (1%), 
hematoma (1.4%),  and seroma (7.1%) were relatively uncommon and much lower than  seen with 
traditional  ALND.  It  was  noted,  however,  that  patients  who  had  five  or  more  SLNs  removed 
experienced increased rates of wound infection and seroma when compared with patients with fewer 
SLNs  removed.   Lymphedema  was  defined  as  an  increase  of  2cm  from  the  presurgical  arm 
measurement when compared with the contralateral arm.  Six-month follow-up data reported axillary 
paresthesia  (8.6%),  decreased  upper  extremity  range  of  motion  (3.8%),and  lymphedema  (6.9%). 
Increasing  age  and  body  mass  index  (BMI)  were  associated  with  an  increased  incidence  of 
lymphedema  after  SLN  biopsy.   Interestingly,  postoperative  adjuvant  radiation  therapy  was  not 
associated significantly with an increased risk of upper extremity lymphedema.  In their report of the 
ACOSOG Z0010 data, Wilke and colleagues  presented an extensive review of the literature regarding 
complications after SLN biopsy versus ALND.  According to their analysis of all available data, the 
incidence of lymphedema after ALND ranges from 7% to 20% as opposed to the low incidence of 
lymphedema noted among the Z0010 patients. 
American College of surgeons Oncology Group Z0011 trial
The American College of surgeons Oncology Group Z0011 trial  was phase III clinical trial for 
clinically node-negative patients with T1 or T2 tumors treated with breast conservation therapy and 
found  to  be  SLN  positive.  Eligible  patients  who  had  a  maximum  of  two  positive  SLNs  were 
randomized to either completion ALND or axillary observation.  The objectives of this study included 
assessing for the possible survival impact of ALND and comparing the morbidity associated with SLN 
biopsy alone versus SLN biopsy with completion ALND.  Unfortunately, after 5 ½ years, Z0011 was 
closed because of poor accrual rates.  A total of 891 patients were enrolled instead of the desired 1900. 
Very few adverse events were reported in either group, requiring a substantial increase in the number 
of patients enrolled in the study.
According to an abstract presented at the 2006 meeting of the American Society of Clinical 
Oncology, 1003 patients from the Z0010 trial were eligible for randomization on Z0011.  Of these, 
only 37% were entered in Z0011. Z0010 participants accounted for 42% of patients in Z0011.  Sixteen 
percent of patients not randomized refused ALND.  Sixty-nine percent of those not randomized had 
ALND.  Sixty-seven percent of these had no additional positive nodes.  Only 14% had more than four 
positive nodes.  In the opinion of the authors, clinical bias in favor of the standard of care, completion 
ALND, likely played a role in the failure to accrue.  Despite this, the data suggest that most patients 
were without additional nodal disease upon completion ALND.  Long-term follow-up data are not yet 
available. 
The American College of Surgeons Oncology Group (ACOSOG) attempted to define the value 
of the ALND in node-positive breast cancer by comparing disease-free survival, overall survival, post 
surgical  morbidity,  and  local  control  in  sentinel  node-positive  patients  randomize  to  axillary 
observation versus the standard completion axillary surgery. The inability to complete this important 
trial likely will strengthen interest in use of statistical models that can identify patients likely to harbor 
additional metastatic nodes following resection of at least one metastatic sentinel node [43, 44].  The 
goal of these prediction tools is to refine the selection of SLN-positive patients who require completion 
ALND.
Axillary Lymphatic Mapping Against Nodal Axillary Clearance Trial 
The  ALMANAC  trial   was  a  multicenter  randomized  study  that  compared  postsurgical 
morbidities and quality-of-life outcomes associated with SLN biopsy versus ALND.  Between 1999 
and 2003, 1031 clinically node-negative breast  cancer patients  were randomized to SLN biopsy or 
standard axillary surgery.  In 2003, the trial was terminated early after it became apparent that patients 
randomized to the SLN arm experienced far less post-surgical morbidity.  Follow-up data are available 
at  1, 3, 6, and 12 months after  surgery.   Initial  reports  indicate that the rated of lymphedema and 
sensory deficit were higher in the ALND group at all time points (P<.001). Shoulder abduction and 
flexion  were  also  worse  in  the  ALND  group  during  initial  follow-up  assessment.   As  mobility 
improved,  these  differences  persisted  at  subsequent  time  points,  but  were  no  longer  statistically 
significant.  Other advantages associated with SLN biopsy included shorter hospital stay, less axillary 
drain usage, and faster return to normal activities of daily living (P<.001 for all three variables).  
NSABP B-32
NSABP B-32 was a large multicenter randomized phase III Clinical trial comparing SLND with 
ALND. With the help over 230 surgeons at 75 participating institutions, over 5600 clinically node-
negative patients were accrued over a 4.5-year period between May 1999 and February 2004.  Eligible 
patients with T1-T3 invasive  cancer were randomized to SLN biopsy followed by ALND versus SLN 
biopsy with ALND only in cases with failed SLN identification or positive SLN.  All Patients who had 
negative SLNs will have further nodal evaluation with immunohistochemistry at a central laboratory. 
The investigators hope to demonstrate that patients who have a histologically negative SLN with no 
further  axillary  surgery  will  have  the  same  long-term  outcomes,  with  less  morbidity,  and  better 
functional outcomes than those patients who subsequently receive a completion  ALND.  Comparisons 
will be made in regards to survival, locoregional control, and postsurgical morbidity.  It is also hoped 
that this study will provide insight as to whether there is prognostic value associated with completion 
ALND after a positive SLN biopsy.  Other secondary goals include confirming the success rate and 
accuracy of the SLN procedure, evaluating the sensitivity and specificity of frozen section evaluation, 
and determining the significance of immunohistochemically detected metastases.
Preliminary data are available regarding technical results in over 5200 patients.  Consistent with 
previous reports in the literature, the overall rate of SLN identification was 97%.  Allergic reactions 
were rare (0.7%). Twenty-six percent of patients possessed positive SLNs, and similar to results from 
Z0011, in 61.5% of the SN-positive patients, no additional positive nodes were found on completion 
ALND.  There was no significant difference in SLN identification rates between the two groups of 
patients.  Further results from this trial are forthcoming. 
Predicting the status of nonsentinel nodes 
Given the uncertainties regarding the survival benefits associated with the completion ALND, a 
valid argument can be made that the critical issue is to identify the subset of high-risk SLN-positive 
who are likely to have  metastases beyond the SLN node.   As mentioned previously.   Menes and 
colleagues [19] identified nonsentinel node metastases in 19% of patients with sentinel node metastases 
less than 0.2mm, 20% of patients with SLN metastases measuring 0.2. mm to 
2 mm, 46% of patients with metastases greater than 2 mm, this dataset demonstrated that in patients 
who are  considered  SLN-negative  (metastases  less  than  0.2 mm) and those  with  micrometastases, 
omitting an axillary dissection may leave residual axllary disease in 20% of patients.  So the logical 
question  arises:  Can we identify patients  with positive SLNs who can  avoid a  completion ALND 
safely?
Van Zee and colleagues [43] therefore developed a nomogram that estimates the likelihood that 
an individual  SLN-positive patient  will  have additional  metastatic  nodes in the completion ALND 
specimen.  Degnim and colleagues [44] conducted a meta-analysis of studies involving SLN biopsy 
with concomitant ALND, and this pooled analysis provides a robust assessment of Clinicopathologic 
features  associated  with likelihood of  detecting metastatic  disease in  nonsentinel  nodes.   Chu and 
colleagues [47] also evaluated clinicopathologic features of 157 patients who underwent SLN biopsy 
followed  by  ALND  to  determine  risk  factors  for  nonsentinel  node  involvement.   All  of  these 
investigators have found primary tumor size and extent of SLN pathology to be strong predictors of 
non-SLN disease.  Despite the fact that the nomogram does not offer treatment recommendations, it 
often is employed  in clinical practice.
Viale and colleagues [48] examined the SLNs and non-SLNs of over 1200 patients in a similar 
fashion to also produce a predictive model.  According to their data.  The size and number of SLN 
metastases and lymphovascular invasion were significant predictors of further axillary involvement.  In 
their opinion, even SLN-positive patients with the lowest possible predicted risk of additional disease 
(13%) should be offered completion axillary lymph node dissection.   Similarly,  other investigators 
have  weighed  in  on  this  issue  with  concordant  results.   Katz  and  colleagues  [49]  conducted  a 
retrospective evaluation of the records of ever 1133 patients undergoing SLN biopsy, which  on 367 
SLN-positive patients.  Increasing number of positive SLNs, decreasing number of negative SLNs, 
increasing size the SLN metastasis, and the presence of lymphovascular invasion were associated with 
the likelihood of finding additional nodal diseases on completion ALND.  The lowest calculated risk of 
additional disease in their study cohort was still 14%. Interestingly, according to their extensive review 
of literature, the rate of non-SLN metastases in patients with sentinel lymph node micrometastases 
ranged  from 0% to  34%.   In  this  study,  Katz  and  colleagues  offered  that  they  also  recommend 
completion axillary lymph node dissection in the setting of a positive SLN until definitive clinical trail 
data stating the contrary are available.
Is there still a role for axillary lymph node dissection?
According to the available data, SLN biopsy is proving to be an accurate staging technique with 
less postsurgical morbidity than standard ALND.  Survival benefits associated with SLN biopsy and 
ALND, and the significance of IHC-detected micrometastases have yet to be determined.  The long-
term results of several multicenter trials are pending, yet preliminary results are in favor of abandoning 
ALND in favor of the less-invasive alternative.
Despite this, ALND remains the standard of care in breast cancer patients who have clinically 
palpable axillary lymph nodes that are suspicious for metastatic disease.  Although controversial, many 
clinicians believe that axillary metastases will precede systemic spread of disease.  Therefore, axillary 
clearance of clinically palpable nodes could quell the progression of metastases.  Regardless of whether 
this theory is true, not many would argue against debulking suspicious nodal disease.
ANATOMY OF THE BREAST
15 to 20 lobes of tubuloalveolar glandular tissue, fibrous connective tissue that supports it lobe, 
and the adipose tissue that resides in parenchyma between the lobes.  Subcutaneous connective tissue 
typically does not form a distinctive capsule around breast components, nut, rather, surrounds the gland 
and extends as septa between the lobes and lobules, providing support to the glandular elements.  The 
deep layer of the superficial facia that lies on the posterior surface of the breast fuses with the deep 
(pectroa)  fasica  of  the  chest  wall.   A  distinct  space,  the  retromammary  bursa,  can  be  identified 
anatomically on the posterior aspect of the breast and resides between the deep layer of the superficial 
facia and the deep investing fascia of the pectoralis major and the contiguous muscles of the thoracic 
wall.  The retromammary bursa contributes to the mobility of the breast on the chest wall.  Fibrous 
thickenings of supportive connective tissue interdigitate between the parenchymal tissue of the breast 
and extend from the deep layer of the superficial fascia to attach to the dermis of the skin.  These 
suspensory structures, known as cooper’s ligaments, insert perpendicular to the dermis, 
SKIN
• THE AREOLA  : Pigmented , sebaceous glands , Montgomery tubercles
• THE NIPPLE  {papilla mammaria}   :
No glands, circumferential muscle fibres , elastic tissue.
• Labia minora matches this skin.
• Lines of Langer
• Dynamic lines of kriasl
                       
        STRUCTURAL ANATOMY
MICROSTRUCTURE
• Tubulo alveolar glands
• Fibrous connective tissue stroma
• Interlobular adipose tissue
                           
GROSS ANATOMY HISTOLOGY PATHOLOGY
Ducts Two layers of columnar 
epithelium 
Papilloma, Ectasia 
Ductules Single layer of cuboidal 
epithelium 
Fibro adenoma, cysts 
sclerosing lesions 
Terminal ductules Cuboidal epithelium Adeno carcinoma 
  
STROMA
INTRALOBULAR  STROMA-  Connective  tissue  stroma  loose  texture  allowing  rapid 
expansion of secretory tissue during pregnancy
 - INTERLOBULAR STROMA- suspensory ligaments {of Ashtley Cooper} condensations of fibrous 
tissue from ducts to dermis, more in the upper quadrants 
ARTERIAL SUPPLY
• Lateral thoracic branch of 2nd part of axillary artery
• Medial mammary branches of internal thoracic artery
• Superior thoracic branch of axillary artery
• Lateral branches of 2nd,3rd,4th posterior intercostal arteries 
VENOUS DRAINAGE
• Circulus venosus - venous plexus deep to the areola
• From this plexus two sets of veins are formed :
1.  superficial set- ends in internal thoracic vein
2.  deep set - ends in internal thoracic, axillary and post intercostal veins
LYMPHATIC DRAINAGE
• AXILLARY NODES- 75 % of lymph
• PARASTERNAL NODES- remaining lymph
• GROUPS –        ANATOMISTS - 5   SURGEONS   - 6        
• lateral or axillary vein group     
• external mammary or  pectoral or medial group
• scapular  or posterior group
• central group
• subclavicular or apical group
• interpectoral or rotter group
 
LEVELS OF AXILLARY NODES
LEVEL 1 NODES:
    lateral to the lateral border of pectoralis minor muscle externalmammary,scapular axillary vein and 
central  groups
LEVEL 2 NODES:
    under the pectoralis minor  muscle   central, axillary group
LEVEL 3 NODES: BERG 
    subclavicular nodes  medial border of pectoralis minor and first rib
                                        
ANATOMY OF AXILLARY TENT
• BASE- Axillary fascia
• APEX- aperture that extends into the posterior triangle of neck thro CERVICO AXILLARY 
CANAL 
• ANTERIOR WALL – Pectoralis muscles and fascia   
• POSTERIOR WALL- Subscapularis , Teresmajor, Lattismus Dorsi.
• LATERAL WALL- Bicipital groove
• MEDIAL WALL- Serratus anterior 
• CLAVIPECTORAL FASCIA:
•  upper portion –COSTOCOROCOID MEMBRANE pierced by  
cephalic vein lateral pectoral nerve, branches of thoraco acromial artery        
Middle portion- pectoralis minor pierced by median pectoral nerve
• Lower portion –CORACO AXILLARY ligament              HALSTEAD 
LIGAMENT- medial side of clavicle to the first rib
• AXILLARY ARTERY: 3 PORTIONS identification of the branches of 2nd portion is essential.
                                                                          
ANATOMICAL STRUCTURES OF IMPORTANCE
• THREE NERVES:                                    
• LONG THORACIC NERVE- medial wall of axilla lies on the serratus anterior fascia . Division 
leads to winging of scapula
• THORACO DORSAL NERVE – origin from posterior cord               supplies lattismus dorsi, 
preservation  essential  for  TRANSFER  SURVIVAL  &MOTOR  FUNCTION  of 
MYOCUTANEOUS FLAP used for lattismus dorsi musculocutaneous reconstruction 
• INTERCOSTO BRACHIAL NERVE- parasthesia of uppermedial and inner aspect of arm
• HALSTEAD LIGAMENT- upper limit of axillary dissection
• branches of 2nd portion of AXILLARY ARTERY – THORACO ACROMIAL & LATERAL 
THORACIC ARTERY .
MATERIALS AND METHODS
STUDY SUBJECT:
                   Biopsy proven carcinoma breast patients admitted at Govt Rajaji Hospital  during the  
period of 2006 to 2008 ,under surgical units 1 to 7 and surgical oncology department with tumour size 
less than 3 cms and clinically axillary node negative status
MAPPING AGENT USED : METHYLENE BLUE    
                  Methylene blue dye was for its low side effects and cost benefit and easy availability
 TECHNIQUE  :    
        7ML of sterile methylene blue was injected 7 minutes before surgery peritumourmally and 
subdermally
PROCEDURE: 
                Under general anesthesia, axillary incision was made  subdermal blue colored lymphatics 
were  traced  upto  the  first  colored  node  (sentinel  node).node  was  dissected  out  and  sent  for 
histopathological examination.
OBSERVATION & DISCUSSION OF THE STUDY
                   The study is a prospective study done in Govt Rajaji Hospital dept of surgery and surgical 
oncology in female patients of carcinoma breast of stage 1(T1NO). The surgery done was MRM along 
with sentinel node biopsy. The dye used was  methylene blue.
                    The technique used was 7ml of the dye was injected seven minutes before surgery, 
peritumourally and subdermally. The patients were proceeded with MRM, first phase of the surgery 
axillary dissection was done and first coloured sentinel node was removed after that MRM continue 
along  with  other  lymphnodes  in  the  axilla  were  dissected.  The  first  coloured  sentinel  node  send 
separately for histopathological examination along with other axillary lymphnodes and breast tissue 
with the mass.   No complications were recorded during the procedure or during the surgery.
                     Review of the histopathology examination of the sentinel node and other axillary nodes 
were indicative of 80% positivity of sentinel node sample  along with other  axillary nodes ,while 
fallacy was noted with negative SLNB and positive axillary nodes in the remainder of the patients.
                  Postoperatively patients were put on 6 cycles of  chemotherapy and harmone therapy and 
followed upto 2years no local recurrence or systemic metastasis were recorded. 
CONCLUSION
                THE STUDY WAS SUCCESSFULLYCOMPLETED AND SHOWS 
ABOUT 80% POSITIVITY OF SLNB (sentinel node positive patients were also 
having positivity of the other axillary node while negative patients had negativity 
of other axillary nodes )
This is was a useful and cost effective study with no major complications 
and reliable technique for day to day practice and having the advantage of ruling 
out radical surgical procedures and major complications post operatively. 
Summary
The value of SLNB in the staging and prognosis  of breast  cancer  patients  with early stage 
disease is defined clearly, and lymphatic mapping is becoming the standard of care for most centers.  It 
is projected that SLNB will soon replace ALND completely as the initial evaluation procedure of the 
axillary nodal basin for metastases.  As the specifics of lymphatic mapping evolve, the process should 
be individualized and tailored to institutional capabilities  and the practice preferences of the entire 
multidisciplinary team to yield the most consistent and reliable results. 
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                                                 PROFORMA
NAME :                                                         AGE :                          SEX :
INPATIENT NO :
UNIT :
DOA :                                                 DOS :
SIDE AND QUADRANT :
SIZE OF THE TUMOUR :
AXILLARY LYMPH NODE STATUS :
STAGE :
DYE USED FOR SLN MAPPING : METHYLENE BLUE
TIME OF INJECTION :  7 MINUTES BEFORE SURGERY
SITE OF INJECTION :  1)SUBDERMAL & PERITUMOURAL
SURGICAL TECHNIQUE :         AXILLARY INCISION FIRST 
FOLLOWED BY MRM
BIOPSY RESULTS :
POST PROCEDURE MANAGEMENT:
FOLLOW UP  :
OUTCOME OF THE STUDY :
CONCLUSION :
ANATOMY
METHYLENE BLUE INJECTION
AXILLARY INCISION
FIRST COLOURED SENTINEL NODE
DISSECTED AXILLARY LYMPHNODES
MASTER CHART
S.No. Name Age Sex IP No. Diagnosis Sentinel 
node HPE 
report
Other 
axillary node 
HPE 
    1) VIJAYALAKSHMI 40 F 46229 CA BREAST RT T1N0M0 Negative Negative
    2) RAJATHI 42 F 562440 CA BREAST RT T1N0M0 Negative Negative
    3) LAKSHMI 40 F 761 CA BREAST LT T2N0M0 Negative Positive
    4) KALANJIYAM 40 F 1156 CA BREAST RT T1N0M0 Positive Positive
    5) MUTHULAKSHMI 41 F 8662 CA BREAST LT T2N0M0 Negative Negative
    6) VALLI 45 F 5170 CA BREASTRT T1N0M0 Positive Positive
    7) ANJAMMAL 36 F 1034 CA BREAST LT T1N0M0 Negative Negative
    8) CHITRA 30 F 11224 CA BREAST LT T1N0M0 Negative Negative
    9) RAJALAKSHMI 47 F 11237 CA BREAST LT T1N0M0 Negative Positive
   10) SUBBUTHAI 38 F 33283 CA BREAST RT T1N0M0 Negative Positive
   11) SUDHA 45 F 33286 CA BREAST LT T1N0M0 Negative Negative
   12) KAMALA 30 F 53302 CA BREAST LT T2N0M0 Negative Negative
   13) PICTHAMMAL 35 F 34778 CA  BREAST RT T1N0M0 Negative Negative
   14) MANIMEGALAI 43 F 35638 CA  BREAST LT T2N0M0 Positive Positive
   15) JOTHIAMMAL 45 F 37082 CA  BREAST RT T1N0M0 Negative Negative
   16) MAHALAKSHMI 48 F 38615 CA  BREAST LT T1N0M0 Negative Positive
   17) BAMA 35 F 40703 CA BREAST LT T1N0M0 Negative Negative
   18) CHELLAIAMMAL 43 F 41797 CA  BREAST RT T1N0M0 Negative Negative
   19) PARAMESHWARI 43 F 100383 CA  BREAST LT T1N0M0 Negative Negative
   20) MALAIYKAL 40 F 94716 CA  BREAST RT T1N0M0 Negative Negative
   21) GOMATHI 39 F 88775 CA BREAST LT T1N0M0 Positive Positive
   22) EASWARI 45 F 47896 CA  BREAST LT T1N0M0 Negative Positive
   23) VALLI 45 F 52391 CA  BREAST  RT T1N0M0 Negative Negative
   24) Selvi 35 F 63450 CA BREAST   LT T1N0M0 Negative Negative
   25) Fathima 60 F 6889 CA  BREAST RT T1N0M0 Negative Negative
   26) Rajammal 60 F 69643 CA  BREAST LT T2N0M0 Negative Positive
   27) Gomathi 45 F 52133 CA  BREAST RT T1N0M0 Positive Positive
   28) Banu 42 F 53134 CA BREAST LT T1N0M0 Negative Negative
  29) Gandhimathi 40 F 52444 CA BREAST RT T1N0M0 Negative Negative
  30) Krishnammal 39 F 53265 CA BREAST RT T1N0M0 Positive Positive

